PubMed

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.

DREAM Trial Investigators, Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T, Keltai M, Lonn E, McFarlane S, McQueen M, Teo K, Sheridan P, Bosch J, Pogue J, Yusuf S.

Diabetes Care. 2008 May;31(5):1007-14. Epub 2008 Feb 11.PMID: 18268075 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).

Lonn EM, Gerstein HC, Sheridan P, Smith S, Diaz R, Mohan V, Bosch J, Yusuf S, Dagenais GR; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) and STARR Investigators.

J Am Coll Cardiol. 2009 Jun 2;53(22):2028-35.PMID: 19477351 [PubMed - indexed for MEDLINE]Related articles

[DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease]

Scheen AJ.

Rev Med Liege. 2006 Oct;61(10):728-32. French. PMID: 17209507 [PubMed - indexed for MEDLINE]Related articles

Effect of ramipril on the incidence of diabetes.

DREAM Trial Investigators, Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR.

N Engl J Med. 2006 Oct 12;355(15):1551-62. Epub 2006 Sep 15.PMID: 16980380 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study.

Rahman S, Ismail AA, Ismail SB, Naing NN, Abdul Rahman AR.

Eur J Clin Pharmacol. 2007 Aug;63(8):733-41. Epub 2007 Jun 13.PMID: 17565489 [PubMed - indexed for MEDLINE]Related articles

Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.

Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J; DREAM Trial Investigators.

Diabetologia. 2004 Sep;47(9):1519-27. Epub 2004 Aug 21.PMID: 15322749 [PubMed - indexed for MEDLINE]Related articles

[Influence of diabetes incidence by ramipril and rosiglitazone: DREAM study (diabetes reduction assessment with ramipril and rosiglitazone medication)]

Standl E, Nitschmann S.

Internist (Berl). 2007 Oct;48(10):1173-6. German. No abstract available. PMID: 17846732 [PubMed - indexed for MEDLINE]Related articles

[The DREAM of diabetes prevention]

Ruiz J.

Rev Med Suisse. 2007 Jan 17;3(94):132, 134-6. French. PMID: 17354538 [PubMed - indexed for MEDLINE]Related articles

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.

Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR; NAVIGATOR Study Group.

Am Heart J. 2008 Oct;156(4):623-32.PMID: 18946890 [PubMed - indexed for MEDLINE]Related articles

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR.

Lancet. 2006 Sep 23;368(9541):1096-105. Erratum in: Lancet. 2006 Nov 18;368(9549):1770. PMID: 16997664 [PubMed - indexed for MEDLINE]Related articles

Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone.

Osei K, Gaillard T, Schuster D.

Metabolism. 2007 Jan;56(1):24-9.PMID: 17161222 [PubMed - indexed for MEDLINE]Related articles

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S.

Ann Intern Med. 2001 Apr 17;134(8):629-36.PMID: 11304102 [PubMed - indexed for MEDLINE]Related articlesFree article

[Progress in the prevention of type 2 diabetes]

Schernthaner G.

Wien Klin Wochenschr. 2003 Nov 28;115(21-22):745-57. Review. German. PMID: 14743578 [PubMed - indexed for MEDLINE]Related articles

Dysglycemia and a history of reproductive risk factors.

McDonald SD, Yusuf S, Sheridan P, Anand SS, Gerstein HC; Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Trial Investigators.

Diabetes Care. 2008 Aug;31(8):1635-8. Epub 2008 May 5.PMID: 18458144 [PubMed - indexed for MEDLINE]Related articlesFree article

Diabetes prevention: still no effective drugs.

[No authors listed]

Prescrire Int. 2007 Dec;16(92):258.PMID: 18095391 [PubMed - indexed for MEDLINE]Related articles

Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients.

Voytovich MH, Simonsen C, Jenssen T, Hjelmesaeth J, Asberg A, Hartmann A.

Nephrol Dial Transplant. 2005 Feb;20(2):413-8. Epub 2004 Dec 22.PMID: 15615809 [PubMed - indexed for MEDLINE]Related articlesFree article

[Experiences of the DREAM trial]

Fövényi J.

Orv Hetil. 2006 Dec 31;147(52):2523-6. Review. Hungarian. PMID: 17294577 [PubMed - indexed for MEDLINE]Related articles

Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management.

Petersen JL, McGuire DK.

Diab Vasc Dis Res. 2005 Feb;2(1):9-15. Review.PMID: 16305067 [PubMed - indexed for MEDLINE]Related articles

Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance.

Bennett SM, Agrawal A, Elasha H, Heise M, Jones NP, Walker M, Wilding JP.

Diabet Med. 2004 May;21(5):415-22.PMID: 15089784 [PubMed - indexed for MEDLINE]Related articles

Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.

McFarlane SI, Provilus A, Shin JJ.

J Cardiometab Syndr. 2007 Spring;2(2):149-50. No abstract available. PMID: 17684471 [PubMed - indexed for MEDLINE]Related articles